Nateglinide

209 interactions 492 cited references

Also sold as: Starlix®

About Nateglinide

Nateglinide is used alone or in combination with other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in people whose diabetes cannot be controlled by diet and exercise alone. Nateglinide belongs to a class o… Read the full Nateglinide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ensitrelvir Abiraterone Acetate Insulin Glulisine (Rdna Origin) Injection Chloroquine Ofloxacin Otic Letermovir Injection

1 Contraindicated 95 Major 112 Moderate 1 Minor

All (209) Contraindicated (1) Major (95) Moderate (112) Minor (1)

Major

Nateglinide Abametapir Increased exposure of CYP3A4 substrate Details Nateglinide Abiraterone Abirtega An increased risk of severe hypoglycemia Details Nateglinide Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Nateglinide Chloroquine Aralen® Hypoglycemia Details Nateglinide Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Nateglinide Delafloxacin Baxdela Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Delafloxacin Injection Baxdela Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Entacapone Comtan Increased exposure of CYP2C9 substrate Details Nateglinide Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Nateglinide Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Nateglinide Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Nateglinide Furosemide Injection Disal An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Gatifloxacin Ophthalmic Zymar® Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Gemifloxacin Factive Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Hydroxychloroquine Plaquenil Enhanced hypoglycemic effect of antidiabetics and an increased risk of hypoglycemia Details Nateglinide Insulin Degludec (Rdna Origin) Injection Ryzodeg® (as a combination product containing Insulin Degludec and Insulin Aspart) An increased risk of hypoglycemia Details Nateglinide Insulin Detemir (Rdna Origin) Injection Levemir An increased risk of hypoglycemia Details Nateglinide Insulin Glulisine (Rdna Origin) Injection Apidra An increased risk of hypoglycemia Details Nateglinide Ketoconazole Topical Extina® Foam Increased nateglinide exposure Details Nateglinide Lanreotide Injection Somatuline An increased risk of hypoglycemia and impaired glucose regulation Details Nateglinide Leniolisib Joenja Increased OATP1B1 substrate exposure Details Nateglinide Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Nateglinide Levofloxacin Levaquin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Levofloxacin Injection Levaquin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Moxifloxacin Avelox Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Moxifloxacin Injection Avelox Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Moxifloxacin Ophthalmic Moxeza® Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Abiraterone Acetate Abirtega An increased risk of severe hypoglycemia Details Nateglinide Abiraterone Acetate, Micronized Abirtega An increased risk of severe hypoglycemia Details Nateglinide Apalutamide Erleada Reduced nateglinide exposure Details Nateglinide Avacopan Tavneos Increased CYP3A4 substrate exposure Details Nateglinide Carbamazepine Carbatrol Reduced CYP3A4/CYP2C9 substrate exposure and reduced efficacy of CYP3A4/CYP2C9 substrate Details Nateglinide Ceritinib Zykadia Increased exposure of CYP3A and CYP2C9 substrate Details Nateglinide Chlorothiazide Diuril An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Chlorthalidone Hemiclor An increased risk of hyperglycemia and an increased insulin requirement Details Nateglinide Ciprofloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Nateglinide Conivaptan Vaprisol Increased CYP3A substrate exposure Details Nateglinide Deutivacaftor Increased CYP2C9 substrate exposure Details Nateglinide Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Nateglinide Elexacaftor Increased OATP1B1 substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.